Since anti-CTLA-4 and anti-PD-L1 use non-redundant mechanisms and act at different time points in the anti-tumour immune response, dual immune checkpoint inhibition in combination with RT may be a future therapeutic option (127). The gene discussed is CTLA4; the disease is neoplasm.